Tirzepatide 10 mg

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Beligas - US
WAREHOUSE USA Warehouse 2
SUBSTANCE GIP/GLP-1 RA

Introducing Tirzepatide, a groundbreaking synthetic peptide designed to effectively lower glucose levels. This innovative compound works by enhancing both first- and second-phase insulin secretion while simultaneously reducing glucagon levels, all in a glucose-dependent manner.

Clinical studies have shown that Tirzepatide can delay gastric emptying, lower fasting and post-meal glucose levels, suppress appetite, and aid in weight loss for those managing type 2 diabetes. Additionally, it may improve insulin sensitivity, making it a valuable ally in diabetes care.

This peptide is uniquely structured with a C20 fatty diacid linked by a hydrophilic connector at the lysine residue in position 20. This configuration allows Tirzepatide to bind strongly to plasma albumin, which significantly prolongs its half-life.

Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are distributed throughout the body, particularly in pancreatic beta-cells and the gastrointestinal tract. They play a vital role in managing glucose levels, enhancing glucose-stimulated insulin secretion, slowing gastric transit, lowering plasma glucagon, and promoting weight loss by reducing appetite through brain pathways. In tandem, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 assist in maintaining glucose homeostasis by stimulating insulin release from pancreatic beta-cells, with GIP primarily driving the insulin response to food intake.

While the exact mechanism of Tirzepatide remains partially understood, its dual action on GIP and GLP-1R is likely crucial for its effectiveness in glycemic control and weight management. Research indicates that combining GIP with a GLP-1R agonist yields a more pronounced insulin response and a greater suppression of glucagon than using either hormone alone. Tirzepatide exhibits a strong binding affinity for both GIP and GLP-1R; laboratory studies reveal its receptor binding affinity for GIP is similar to that of native GIP, albeit with a five-fold lower efficacy at binding GLP-1R compared to native GLP-1. Tirzepatide effectively activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion via either GIP receptor (GIPR) or GLP-1R. Further research is essential to fully understand the role of GIPR activation in its mechanism, as current evidence regarding its effects on glycemic control and weight management varies across both preclinical and clinical studies.